Anika Therapeutics, Inc. (ANIK) Stock Price & Analysis
Anika Therapeutics, Inc. (ANIK) rose 1.91% to USD 14.95 as of July 25, 2026 at 20:11 UTC, according to Nexqual real-time market data.
ANIK last closed at USD 14.67; the session ranged USD 14.58–15.11 on volume of 39,841 shares. Market capitalization is $198.92M, with a 52-week range of USD 7.87–16.49 (NMS). Source: Nexqual, July 25, 2026 at 20:11 UTC.
Key Statistics (as of July 25, 2026 at 20:11 UTC)
| Price | USD 14.95 |
|---|---|
| Change | ▲ 1.91% (up) |
| Previous Close | USD 14.67 |
| Open | USD 14.74 |
| Day Range | USD 14.58 – 15.11 |
| 52-Week Range | USD 7.87 – 16.49 |
| Volume | 39,841 shares |
| Market Cap | $198.92M |
| Exchange | NMS |
Technical Analysis (ANIK)
Nexqual's technical model rates ANIK "SELL" based on 2 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 20:11 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 47.01 (neutral) |
| vs SMA50 | Below (USD 14.99) |
| MACD | 0.02 (positive) |
Analyst Ratings (ANIK)
Wall Street analysts rate ANIK "None" based on 2 analysts, with a mean price target of USD 17.5 (range USD 17–18), per Nexqual as of July 25, 2026 at 20:11 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 17.5 |
| High Target | USD 18 |
| Low Target | USD 17 |
| Buy / Hold / Sell | 2 / 0 / 0 |
Earnings (ANIK)
| Next Earnings Date | 2026-07-29 |
|---|---|
| EPS Estimate | USD 0.03 |
| Revenue Estimate | $29.21M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.27 vs est 0 ▲ beat |
| 2025-12-31 | USD 0.31 vs est 0.02 ▲ beat |
| 2025-09-30 | USD 0.04 vs est 0.02 ▲ beat |
| 2025-06-30 | USD -0.13 vs est -0.13 ▲ beat |
Source: Nexqual, July 25, 2026 at 20:11 UTC.
Financials & Fundamentals (ANIK)
| Total Revenue | $116.26M |
|---|---|
| Revenue Growth (YoY) | +13.20% |
| Gross Margin | +58.59% |
| Operating Margin | -13.17% |
| Profit Margin | -9.52% |
| ROE | -7.85% |
| Debt / Equity | 19.22 |
| Current Ratio | 4.46 |
| Total Cash | $41.02M |
| Total Debt | $25.74M |
| Free Cash Flow | $7.35M |
Source: Nexqual, July 25, 2026 at 20:11 UTC.
Financial Health Score (ANIK)
Nexqual rates Anika Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 20:11 UTC.
| Growth | Weak — Revenue -6% YoY (annual), declining |
|---|---|
| Profitability | Mixed — Gross margin 59%, operating -13% |
| Balance Sheet | Strong — $41M cash vs $26M debt, net cash position |
| Cash Flow | Solid — FCF $7M, 7% margin |
| Efficiency | Critical — ROE -8%, ROA -3.6% |
Ownership (ANIK)
| Insider Ownership | +6.42% |
|---|---|
| Institutional Ownership | +94.76% |
| Shares Outstanding | 13.31M |
| Float | 11.21M |
| Short % of Float | +3.46% |
Source: Nexqual, July 25, 2026 at 20:11 UTC.
Leadership (ANIK)
Anika Therapeutics, Inc. is led by Stephen D. Griffin (age 39), President, Principal Financial Officer, CEO & Director, per Nexqual as of July 25, 2026 at 20:11 UTC.
| President, Principal Financial Officer, CEO & Director | Stephen D. Griffin (age 39) |
|---|---|
| Executive Director of Corporate Development & Investor Relations | Matthew Hall |
| Senior Vice President of Commercial | Ben Joseph |
| Senior Vice President of Regulatory, Quality & Clinical Affairs | Mira Leiwant |
Major Backers & Investors (ANIK)
Notable institutional backers of Anika Therapeutics, Inc. include Caligan Partners, LP, Morgan Stanley, Acadian Asset Management. LLC, according to Nexqual as of July 25, 2026 at 20:11 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Caligan Partners, LP | 10.79% |
| Morgan Stanley | 6.55% |
| Acadian Asset Management. LLC | 4.56% |
| Boothbay Fund Management, LLC | 3.98% |
| Renaissance Technologies | 3.77% |
| Capital Management Corporation | 3.36% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 15.07% |
| Vanguard Group | 9.46% |
| Dimensional Fund Advisors | 3.45% |
| Deutsche Bank AG | 2.65% |
Source: Nexqual, July 25, 2026 at 20:11 UTC.
From Anika Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-03)
Key Strengths & Strategy (as disclosed to the SEC)
- Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENTA | Enanta Pharmaceuticals, Inc. | USD 12.78 | ▼ 2.14% |
| ANIP | ANI Pharmaceuticals, Inc. | USD 77.65 | ▲ 0.05% |
| ANGO | AngioDynamics, Inc. | USD 13.59 | ▼ 1.66% |
| ALKS | Alkermes plc | USD 52.89 | ▲ 0.59% |
| OFIX | Orthofix Medical Inc. | USD 11.25 | ▲ 2.09% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 20:11 UTC. This page is informational and not investment advice.